ArticleACS nano2025
Heparin-Binding Proteins in the Nanoparticle Corona Enhance Cellular Uptake through Glycocalyx Interactions.
Article in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticles (NPs) designed for intracellular delivery must first navigate the cell-surface glycocalyx before reaching the plasma membrane for internalization. Here, we hypothesized that the glycocalyx can both hinder NP uptake via a barrier effect and enhance uptake by providing recognition sites for corona proteins. To dissect these opposing mechanisms, we prepared NPs with plasma protein coronas either enriched or depleted in heparin-binding proteins (HBPs), along with model coronas containing selected HBPs or non-HBPs. Biophysical assays confirmed strong heparin interactions for HBP-rich NPs, whereas HBP-poor NPs showed weak or no binding. To assess the role of corona-glycocalyx interactions in NP uptake, we used glycocalyx-depleted cells, a chemical inhibitor, and heparin and antithrombin competition assays. We found that canonical HBPs within the protein corona, including antithrombin, apolipoprotein E, and platelet factor 4, significantly enhanced NP surface retention and internalization through protein-glycocalyx interactions. In contrast, HBP-poor NPs showed weak or no interactions with the glycocalyx and, correspondingly, reduced uptake. Significantly, these findings also extended to physiologically derived coronas from control and dyslipidemic sera, with the latter producing HBP-enriched coronas that bound more strongly to heparin and promoted more efficient glycocalyx-dependent NP uptake. These findings highlight the underappreciated role of the glycocalyx in actively engaging with coronal HBPs to drive efficient NP uptake. This insight underscores the need to expand corona engineering beyond membrane receptor interactions, incorporating strategies that optimize glycocalyx interactions for more effective NP delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.